| Vismodegib, sold under the brand name Erivedge, is a medication used for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011. The drug was developed by the biotechnology/pharmaceutical company Genentech. |
|
Read full article at Wikipedia
|
InChI=1S/C19H14Cl2N2O3S/c1- 27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) |
| BPQMGSKTAYIVFO-UHFFFAOYSA-N |
| CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1 |
|
|
SMO receptor antagonist
An antagonist that interferes with the action of smoothened (SMO) receptor.
teratogenic agent
A role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.
Hedgehog signaling pathway inhibitor
Any pathway inhibitor that inhibits the Hedgehog signalling pathway.
|
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
|
2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide
|
|
vismodegib
|
KEGG DRUG
|
vismodégib
|
WHO MedNet
|
vismodegib
|
WHO MedNet
|
vismodegibum
|
WHO MedNet
|
|
12532124
|
Reaxys Registry Number
|
Reaxys
|
|
879085-55-9
|
CAS Registry Number
|
KEGG DRUG
|
|
879085-55-9
|
CAS Registry Number
|
ChemIDplus
|
|
